Objective To observe the influence of sakubatril-valsartan sodium on changes of left ventricular end-diastolic diameter(LVEDd)in patients with chronic heart failure(CHF).Methods CHF patients(n=90)were chosen from Department of Cardiovascular Medicine in Huainan Chaoyang Hospital of Anhui Province from Feb.2020 to June 2023,and they were divided routine group and Entresto group(each n=45).The routine group was treated with routine therapy,and Entresto group was additionally treated with sakubatril-valsartan sodium.The differences in serum factors[interleukin-10(IL-10),C-reactive protein(CRP),N-terminal pro-brain natriuretic peptide(NT-proBNP),tumor necrosis factor-α(TNF-α)],6-minute walk test(6MWT),and indexes of left ventricular remodeling[left ventricular ejection fraction(LVEF),LVEDd,left atrial anteroposterior diameter(LAAPd),left ventricular end-diastolic volume(LVEDV),left ventricular mass index(LVMI),left ventricular end-systolic volume(LVESV),left ventricular myocardial performance]were compared between 2 groups before and after treatment.Results The differences in IL-10,NT-proBNP and 6MWT had no statistical significance between 2 groups before treatment(P＞0.05).The levels of serum factors decreased,and 6MWT increased in 2 groups after treatment,which was more significant in Entresto group(P＜0.05).The differences in indexes of left ventricular remodeling and left ventricular myocardial performance had no statistical significance between 2 groups before treatment(P＞0.05).The levels of LVEF and left ventricular global work index(GWI),global effective work(GCW)and global work efficiency(GWE)increased,and LVEDd,LAAPd,LVEDV,LVMI,LVESV and left ventricular global ineffective work(GWW)decreased in 2 groups after treatment,which was more significant in Entresto group(P＜0.05).Conclusion Sakubatril-valsartan sodium can inhibit left ventricular remodeling,improve left ventricular myocardial performance and promote exercise endurance in CHF treatment.
维普
万方数据